Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: Design, synthesis, and biological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 1, 2007, Pages 278-281

  Liu, Tao ^a   Xu, Zhongmiao ^a   He, Qiaojun ^a   Chen, Yanhong ^a   Yang, Bo ^a   Hu, Yongzhou ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antiproliferative activity; Apoptosis; Cyclin dependent kinases (CDKs) inhibitor; Flavonoids

Indexed keywords

5 HYDROXY 7 METHOXYFLAVONE DERIVATIVE; CHALCONE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHOXYFLAVONE DERIVATIVE; FLAVONOID; NITROGEN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL;

CDC2 PROTEIN KINASE; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN B; DRUG DESIGN; FLAVONOIDS; HUMANS; NITROGEN; PROTEIN KINASE INHIBITORS;

EID: 33845612219     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.088     Document Type: Article

References (21)

1. Harper J.W., and Adams P.D. Chem. Rev. 101 (2001) 2511
2. Sielecki T.M., Boylan J.F., Benfiled P.A., and Trainor G.T. J. Med. Chem. 43 (2000) 1
3. Moon M.J., Lee S.K., Lee J.W., Song W.K., Kim S.W., Kim J.I., Cho C., Choi S.J., and Kim Y.C. Bioorg. Med. Chem. 14 (2006) 237
4. Zhai S., Senderowicz A.M., Sausville E.A., and Figg W.D. Ann. Pharmacother. 36 (2002) 905
5. Murthi K.K., Dubay M., McClure C., Brizuela L., Boisclair M.D., Worland P.J., Mansuri M.M., and Pal K. Bioorg. Med. Chem. Lett. 10 (2000) 1037
6. Huwe A., Mazitschek R., and Giannis A. Angew. Chem., Int. Ed. 42 (2003) 2122
7. Pouget C., Lauthier F., Simon A., Fagnere C., Basly J.P., Delage C., and Chulia A.J. Bioorg. Med. Chem. Lett. 11 (2001) 3095
8. Rao Y.K., Fang S.H., and Tzeng Y.M. Bioorg. Med. Chem. 13 (2005) 6850
9. Gulati K.C., Seth S.R., and Venkataraman K. Org. Synth. Coll. Vol. 2 (1943) 522
10. Juntend, K. Y. T.; Junte, T. S. T. E.P. Patent 292,576, 1988; Chem. Abstr. 1988, 110, 23539.
11. Bu X.Y., Zhao L.Y., and Li Y.L. Synthesis 11 (1997) 1246
12. Wilds A.L., Nowak R.M., and McCaleb K.E. Org. Synth. Coll. Vol. 4 (1963) 281
13. Li J.F., Mao G.J., and Miao Y.Y. Heilongjiang Med. Pharm. 25 (2002) 15
14. Solladie G., Gehrold N., and Maignan J. Tetrahedron: Asymmetry 10 (1999) 2739
15. Liu T., Xu Z.M., and Hu Y.Z. Acta Crystallogr., Sect. E (2005) 3389 CCDC deposition number 287623
16. +.
17. CDK1/Cyclin B kinase assay procedure: Add 3000 nM, 300 nM, and 30 nM of tested compounds to the wells, respectively, and incubate for 30 min at 30 °C. Wash the wells with wash buffer. Add 100 μL of Anti-phospho Cdc7 T376 Monoclonal Antibody TK-3H7, incubate for 30 min at room temperature. Wash the wells with wash buffer again. Add 100 μL of HRP-conjugated anti-mouse IgG, incubate for 30 min at room temperature. Wash the wells with wash buffer again. Add 100 μL of substrate reagent and incubate for 5-15 min at room temperature. Add 100 μL of stop solution. Measure absorbance at 450 nm.
18. Mosman T. J. Immunol. Methods 55 (1983) 5563
19. Sielecki T.M., Boylan J.F., Benfield P.A., and Trainor G.L. J. Med. Chem. 43 (2000) 1
20. Lee S.K., Heo Y.H., Steele V.E., and Pezzuto J.M. Anticancer Res 22 (2002) 97
21. Ye F., Wu J., Dunn T., Yi J.-Z., Tong X.-D., and Zhang D. Cancer Lett. 211 (2004) 39